Pharmaron Beijing Co., Ltd — Capital/Financing Update 2021

Jun 18, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “ Securities Act ”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “ Regulation S ”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being or will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.

==> picture [117 x 33] intentionally omitted <==

Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 3759)

COMPLETION OF ISSUE OF US$300.0 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026; AND

COMPLETION OF ISSUE OF RMB1,916.0 MILLION ZERO COUPON US$-SETTLED CONVERTIBLE BONDS DUE 2026

Reference is made to the announcement of Pharmaron Beijing Co., Ltd. (康龍化成（北京）新藥 技術股份有限公司) (the “ Company ”) dated June 8, 2021 and June 9, 2021 in relation to the proposed issued of the Series 1 Bonds and the Series 2 Bonds (the “ Announcements ”). Unless otherwise defined, all terms used herein shall have the same meanings as those defined in the Announcements.

The Board is pleased to announce that all the conditions precedent under the Subscription Agreement have been fulfilled and the issue of the Series 1 Bonds and Series 2 Bonds in an aggregate principal amount of US$300 million and RMB1,916 million, respectively was completed on June 18, 2021. The net proceeds from the Subscription of the Bonds, after the deduction of fees, commissions and expenses payable, will be approximately US$587.5 million. The Company intends to use the proceeds from the Subscription in the manner detailed in the paragraph headed “Use of Proceeds” of its announcement dated June 9, 2021 and the paragraph headed “Allocation of Proceeds to the Proposed Used of Proceeds” in its announcement dated June 11, 2021.

1

The listing and permission to deal in the Bonds on the Hong Kong Stock Exchange is expected to become effective on June 21, 2021.

By Order of the Board Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司 Dr. LOU Boliang* Chairman

Beijing, the PRC June 18, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors, Mr. CHEN Pingjin, Mr. HU Baifeng, Mr. LI Jiaqing and Mr. ZHOU Hongbin as non-executive Directors, and Mr. DAI Lixin, Ms. CHEN Guoqin, Mr. TSANG Kwan Hung Benson and Mr. YU Jian as independent nonexecutive Directors.

• For identification purposes only

2